Market Dynamics of Companion Diagnostics: Drivers, Challenges, and Industry Forecast
The Companion Diagnostics Market is increasingly recognized for its role in improving drug safety. These diagnostic tests help identify patients who are likely to respond positively to a drug, while also flagging those who may experience severe adverse reactions. This capability is vital in preventing unnecessary health risks and minimizing hospital admissions caused by inappropriate drug prescriptions.
The approach is particularly important in oncology, where certain targeted therapies can have significant side effects if administered to unsuitable patients. As a result, regulators and healthcare providers are pushing for more integrated use of companion diagnostics before therapy initiation. With the growing availability of genetic testing and biomarker-based analysis, drug safety measures are set to become more personalized and effective.